NewLink Genetics Corporation, a biotech developing a Phase 3 drug for surgically-resected pancreatic cancer patients, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering. The Ames, IA-based company, which was founded in 1999 and booked $2 million in grant revenue for the 12 months ended September 30, plans to list on the NASDAQ under the symbol NLNK. Wells Fargo Securities and Cowen & Company are the lead underwriters on the deal, for which pricing terms and timing were not disclosed.
